학술논문

Episignatures Stratifying Helsmoortel-Van Der Aa Syndrome Show Modest Correlation with Phenotype
Document Type
article
Source
American Journal of Human Genetics. 107(3)
Subject
Biological Sciences
Biomedical and Clinical Sciences
Genetics
Human Genome
Brain Disorders
Basic Behavioral and Social Science
Intellectual and Developmental Disabilities (IDD)
Mental Health
Behavioral and Social Science
Autism
Neurosciences
Clinical Research
Aetiology
2.1 Biological and endogenous factors
Neurological
Autism Spectrum Disorder
Child
DNA Methylation
Developmental Disabilities
Epigenesis
Genetic
Female
Homeodomain Proteins
Humans
Intellectual Disability
Male
Mutation
Nerve Tissue Proteins
Neurodevelopmental Disorders
Phenotype
Transcriptome
ADNP
DNA methylation
Helsmoortel-Van der Aa syndrome
autism spectrum disorder
biomarkers
epigenetic signature
episignature
genotype-phenotype correlations
intellectual disability
neurodevelopmental disorders
Medical and Health Sciences
Genetics & Heredity
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
Helsmoortel-Van der Aa syndrome (HVDAS) is a neurodevelopmental condition associated with intellectual disability/developmental delay, autism spectrum disorder, and multiple medical comorbidities. HVDAS is caused by mutations in activity-dependent neuroprotective protein (ADNP). A recent study identified genome-wide DNA methylation changes in 22 individuals with HVDAS, adding to the group of neurodevelopmental disorders with an epigenetic signature. This methylation signature segregated those with HVDAS into two groups based on the location of the mutations. Here, we conducted an independent study on 24 individuals with HVDAS and replicated the existence of the two mutation-dependent episignatures. To probe whether the two distinct episignatures correlate with clinical outcomes, we used deep behavioral and neurobiological data from two prospective cohorts of individuals with a genetic diagnosis of HVDAS. We found limited phenotypic differences between the two HVDAS-affected groups and no evidence that individuals with more widespread methylation changes are more severely affected. Moreover, in spite of the methylation changes, we observed no profound alterations in the blood transcriptome of individuals with HVDAS. Our data warrant caution in harnessing methylation signatures in HVDAS as a tool for clinical stratification, at least with regard to behavioral phenotypes.